Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): A Brazilian multicentre cohort study

Lupus

Volumn 16, Issue 7, 2007, Pages 531-536

  Da Silva, Clovis Artur Almeida ^a,d   Hilario M O ^b   Febronio M V ^a   Oliveira, S K ^c   Terreri, M T ^b   Sacchetti, S B ^d   Sztajnbok, F R ^e   Marini, R ^f   Quintero, M V ^d   Bica, B E ^c   Pereira, R M ^a   Bonfa E ^a   Ferriani, V P ^a   Robazzi, T C ^g   Magalhaes C S ^h  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d Santa Casa of São Paulo ^*  (Brazil)

^e STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g HOSPITAL SÃO RAFAEL   (Brazil)

^h SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Adolescent; Amenorrhea; Cyclophosphamide; Gonadal function; Juvenile systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE;

AMENORRHEA; ARTICLE; BRAZIL; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; OVARY FOLLICLE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGE OF ONSET; AMENORRHEA; BIOLOGICAL MARKERS; BRAZIL; CHILD; ESTRADIOL; FEMALE; FLUOROIMMUNOASSAY; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUTEINIZING HORMONE; MENSTRUAL CYCLE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 34547741601     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079300     Document Type: Article

References (26)

1. Gurtcheff S, Hatasaka H. Fertility and autoimmune disease. In Lockshin M, Branch W eds. Handbook of systemic autoimmune disease. Reproductive and hormonal aspects of systemic autoimmune disease, Vol. 4. Elsevier, 2006; 29-42.
2. Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219-228.
3. Pasoto SG, Mendonca BB, Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002; 11: 175-180.
4. Medeiros MM, Silveira VA, Menezes AP, Carvalho RC. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 2001; 34: 1561-1568.
5. Metcalf MG, Skidmore D, Lowry GF, Mackenzie JA. Incidence of ovulation in the years after the menarche. J Endocrinol 1983; 97: 213-219.
6. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004; 13: 569-574.
7. Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E. Anticorpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus?. J Rheumatol 1999; 26: 1087-1093.
8. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-369.
9. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-14.
10. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224-229.
11. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831-837.
12. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002; 29: 2129-2135.
13. Huong du L, Amoura Z, Duhaut P et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29: 2571-2576.
14. Silva CA, Leal MM, Simone VP et al. Gonadal function in adolescents and young female with systemic lupus erythematosus. Lupus 2002; 11: 419-425.
15. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34: 737-741.
16. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-444.
17. Brunner HI, Bishnoi A, Barron AC et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15: 198-206.
18. Ravelli A, Duarte-Salazar C, Buratti S et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003; 49: 501-507.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthrits Rheum 1997; 40: 1725.
20. Niaudet P. Treatment of lupus nephritis in children. Pediatric Nephrology 2000; 14: 158-166.
21. Bombardier C, Gladman DD, Urowitz MB, Karon D, Chang CH and The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
22. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Sensitivity of the Systemic Lupus Erytematosus Disease Activity Index, British Isles Lupus Assessement Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erytematosus. Arthrits Rheum 1999; 42: 1354-1360.
23. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
24. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-2557.
25. Kim YK, Wasser SK, Fujimoto VY, Klein NA, Moore DE, Soules MR. Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and FSH:LH ratio in predicting reproductive age in normal women. Hum Reprod 1997; 12: 1152-1155.
26. de Medeiros SF, Assi PE, de Medeiros MM. Gonadotrophin dynamics during reproductive life. Int J Gynaecol Obstet 2004; 87: 24-28.